Terremoto Biosciences, Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- Biotech
- Headquarters
- South San Francisco, CA
- Street
- 230 East Grand Avenue, Suite 200
- Zip
- 94080
Offering
- Total offering
- $108.6M
- Amount sold
- $40.7M
- First sale
- Apr 10, 2026
- Min investment
- $0
- Securities
- Equity
- Federal exemption
- Rule 506(b)
- Investors so far
- 14
How this filing compares
Ranked #2 of 47 Biotech filings in April 2026 by offering amount.
Median Biotech filing in April 2026: $3M. This offering is 36.2× the median.
Other California filings this week: 444 Capital - D'Amelio Family Fund I, LP, Angeles Private Markets Fund 6 LP, AQT Capital Fund, LP, C1 Group LLC, Camden Bonds Plus Fund, LLC
Leadership
Charles Baum — Executive Officer (also: Director)
James Christensen — Executive Officer (also: Director)
Grace Lu — Executive Officer
Reid Huber — Director
Daniel O'Connell — Director
Peter Thompson — Director
Michael Goller — Director
Filing details
Terremoto Biosciences, Inc. filed a Form D with the SEC on April 22, 2026.